Related Experiment Video
Updated: Dec 3, 2025
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
6.2K
Transanal total mesorectal excision: 3-year oncological outcomes
S Ourô1,2,3, D Albergaria4,5, M P Ferreira4
1Surgical Department of Hospital Beatriz Ângelo, Loures, Portugal. smrouro@gmail.com.
Techniques in Coloproctology
|October 28, 2020
Summary
Transanal total mesorectal excision (TaTME) offers safe mid-term oncological outcomes for rectal cancer patients. This novel surgical approach demonstrates promising survival rates and low recurrence, supporting its standardized implementation.
Area of Science:
- Colorectal Surgery
- Surgical Oncology
- Rectal Cancer Research
Background:
- Rectal cancer treatment is advancing with new surgical techniques.
- Transanal total mesorectal excision (TaTME) is a recent approach for pelvic dissection in mid- and distal rectal tumors.
Purpose of the Study:
- To analyze the short- and mid-term oncological outcomes of Transanal total mesorectal excision (TaTME).
Main Methods:
- Retrospective analysis of clinical, pathological, and oncological data from 50 patients treated with TaTME for rectal cancer.
- Primary endpoints included 3-year overall survival, disease-free survival, and local recurrence.
Main Results:
- 98% of patients had complete or near-complete mesorectum with R0 resections.
- Median follow-up was 36 months, with 4% local recurrence.
- Estimated 3-year overall survival was 90% and disease-free survival was 79%.
Conclusions:
- Transanal total mesorectal excision (TaTME) provides safe mid-term oncological outcomes comparable to traditional TME.
- The study highlights the demanding nature of TaTME and the need for audited data and standardized implementation.
